Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Akebia Therapeutics's share price for the quarter that ended in Dec. 2023 was $1.24. Akebia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 194.6 Mil. Therefore, Akebia Therapeutics's market cap for the quarter that ended in Dec. 2023 was $241.3 Mil.
Akebia Therapeutics's quarterly market cap
increased
from Jun. 2023 ($172.1 Mil) to Sep. 2023 ($214.7 Mil) and
increased
from Sep. 2023 ($214.7 Mil) to Dec. 2023 ($241.3 Mil).
Akebia Therapeutics's annual market cap
declined
from Dec. 2021 ($400.0 Mil) to Dec. 2022 ($106.2 Mil) but then
increased
from Dec. 2022 ($106.2 Mil) to Dec. 2023 ($241.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Akebia Therapeutics's Enterprise Value for Today is $296.2 Mil.
Akebia Therapeutics Market Cap Historical Data
The historical data trend for Akebia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Akebia Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Market Cap
768.99
414.61
400.02
106.25
241.28
Akebia Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Market Cap
106.25
104.14
172.14
214.68
241.28
Competitive Comparison
For the Biotechnology subindustry, Akebia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Market Cap falls into.
Akebia Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Akebia Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (NAS:AKBA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Akebia Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics (Akebia Therapeutics) Business Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKBA has been successfully added to your 